This MedLibrary.org supplementary page on Anidulafungin is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
|
|
Anidulafungin
|
|
| Systematic (IUPAC) name | |
| ? | |
| Identifiers | |
| CAS number | |
| ATC code | J02 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C58H73N7O17 |
| Mol. mass | 1140.24 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 84% |
| Metabolism | ? |
| Half life | 40-50 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Anidulafungin or Eraxis (Ecalta in Europe) is an anti-fungal drug manufactured by Pfizer that gained approval by the Food and Drug Administration (FDA) in February 21, 2006 [1]; it was previously known as LY303366. There is preliminary evidence that it has a similar safety profile to caspofungin. It has proven efficacy against oesophageal candidiasis, but its main utility will probably be in invasive Candida infection; it will probably also have application in treating invasive Aspergillus infection. It is a member of the class of anti-fungal drugs known as the echinocandins: its mechanism of action is by inhibition of (1→3)β-D-glucan synthase, which is an important component of the fungal cell wall.
Pharmacokinetics
Anidulafungin significantly differs from other antifungals in that it undergoes chemical degradation to inactive forms at body pH and temperature. Because it does not rely on enzymatic degradation or hepatic or renal excretion, the drug is safe to use in patients with any degree of hepatic or renal impairment.[1]
References
- Krause DS, Reinhardt J, Vazquez JA, Reboli A, Goldstein BP, Wible M, Henkel T (2004). "Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia". Antimicrob Agents Chemother 48 (6): 2021–4. doi:. PMID 15155194.
- Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ (2005). "In Vitro Activities of Anidulafungin against More than 2,500 Clinical Isolates of Candida spp., Including 315 Isolates Resistant to Fluconazole". J Clin Microbiol 43 (11): 5425–7. doi:. PMID 16272464.
- Pfaller MA, Diekema DJ, Boyken L, Messer SA, Tendolkar S, Hollis RJ, Goldstein BP (2005). "Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis". Antimicrob Agents Chemother 49 (11): 4795–7. doi:. PMID 16251335.
|
|||||||||||||||||||||||||||
 |
This antimicrobial-related article is a stub. You can help Wikipedia by expanding it. |
Wikipedia content modification information:
- This page was last modified on 5 September 2008, at 23:35.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Anidulafungin".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.